Abstract Number: 2897 • 2019 ACR/ARP Annual Meeting
Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease with various subsets and clinical manifestations. T lymphocytes are the predominant cell type found in lesional…Abstract Number: 2898 • 2019 ACR/ARP Annual Meeting
Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis
Background/Purpose: The impact of renal injury in lupus nephritis (LN) is widespread with consequences to resident cells in other tissue beds, even non-lesional, non-sun exposed…Abstract Number: 2899 • 2019 ACR/ARP Annual Meeting
Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation
Background/Purpose: Systemic lupus erythematosus (SLE) affects various organs and tissues, but whether pathologic processes in each organ are distinct or whether dysregulated molecular functions are…Abstract Number: 2900 • 2019 ACR/ARP Annual Meeting
Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20
Background/Purpose: The protein A20, encoded by TNFAIP3, represses signaling upstream of the inflammatory transcription factor nuclear factor (NF)-kB by regulating ubiquitination. Heterozygous loss-of-function mutations in…Abstract Number: 2901 • 2019 ACR/ARP Annual Meeting
Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience
Background/Purpose: The main goal of Familial Mediterranean Fever (FMF) treatment is to prevent attacks and subclinical inflammation. Mainstay of treatment is colchicine; however, 5-10% of…Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…Abstract Number: 2903 • 2019 ACR/ARP Annual Meeting
Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission
Background/Purpose: Targeting the interleukin(IL)-1 pathway with anti-IL-1 drugs is a treatment option in patients with autoinflammatory diseases like monogenic periodic fever syndromes. The study aims…Abstract Number: 2904 • 2019 ACR/ARP Annual Meeting
Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality and carries significant morbidity in connective tissue disease (CTD). Corticosteroids are often used as…Abstract Number: 2905 • 2019 ACR/ARP Annual Meeting
Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects…Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…Abstract Number: 2910 • 2019 ACR/ARP Annual Meeting
Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
Background/Purpose: Efficiently identifying eligible patients is an important component of a successful clinical trial. Billing codes from electronic health record (EHR) data are commonly used…Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
ACR Meeting Abstracts